Search for Predictors of Therapeutic Response in Ovarian Carcinoma

Centre Francois Baclesse107 enrolled

Overview

In order to search for predictors of response to chemotherapy in patients with ovarian carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced stage, we will define the comparative profiles of miRNA expression of serum polymorphisms and determine differential in 2 patient populations (with or without recurrence 6 months after completion of chemotherapy) with (i) the miRNA profile of serum before treatment and (ii) identification of polymorphisms or SNP (Single Nucleotide Polymorphism) in particular genes involved in the metabolism of chemotherapy agents In the case of miRNA, expression profiles will also be studied during the first course in response to chemotherapy. Indeed, the miRNA profile of serum may be different at baseline among the 2 types of populations (or non-recurrence at 6 months).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Masking

NONE

Enrollment

107

Conditions

Carcinoma of the Ovary Fallopian Tube Cancer Peritoneal Serous-type Advanced Stage

Interventions

blood samplesOTHER

blood samples in patients receiving Taxol and carboplatin chemotherapy : * On Day 1 of the first course of chemotherapy * On Day 1 of the second course of chemotherapy * Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy * At the end of chemotherapy

blood samplesOTHER

blood samples in patients receiving Taxol and carboplatin chemotherapy with avastin: * On Day 1 of the first course of chemotherapy * On Day 1 of the second course of chemotherapy * Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy * At the end of chemotherapy

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with cancer of the ovary, peritoneum or of the fallopian tube * Stage III or IV * Cancer of serous histology * Patients of any chemotherapy naive * Patients should receive treatment with chemotherapy for first line by Taxol- Carboplatin. Avastin is authorized in concomitant. * An initial surgery or through authorized * Patients who signed informed consent * Patients over the age of 18 years Exclusion Criteria: * Patients being treated for another cancer chemotherapy and / or hormone therapy * Patients receiving other chemotherapy Taxol-carboplatin associated or not to avastin * Patients under guardianship * Previous history of pelvic radiotherapy * History of malignancy blood

Locations (7)

Centre Eugène Marquis

Rennes, Brittany Region, France

Centre François BACLESSE

Caen, Calvados, France

Centre Réné Gauducheau

Nantes, Loire-Atlantique, France

Centre Oscar LAMBRET

Lille, Nord, France

Centre Henri Becquerel

Rouen, Seine Maritime, France

Institut de cancerologie de la loire

Angers, France

Institut CURIE

Paris, France

Outcomes

Primary Outcomes

search for predictors of response to chemotherapy

the search for predictors of response to chemotherapy in patients with carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced by using (i) the miRNA profile of serum before treatment with chemotherapy and (ii) the identification of polymorphisms or SNPs (Single Nucleotide polymorphism) in particular genes involved in the metabolism of chemotherapy agents

Time frame: 12 months after beginning treatment

Secondary Outcomes

profiling miRNA expression

\- Characterization of the response to treatment with profiling miRNA expression after the first course of chemotherapy in patients with carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced

Time frame: 1 month

study of changes in serum miRNA expression

\- The study of changes in serum miRNA expression identified as predictive of tumor response during chemotherapy treatment.

Time frame: 6 months